Cuatrecasas guides Arcline Investment´s acquisition of PTS
Cuatrecasas has advised Arcline Investment Management on its acquisition of Polypeptide Therapeutic Solutions from Columbus Venture Partners
Arcline Investment Management, a growth-oriented Private Equity firm with $4.3 billion of cumulative capital commitments, with offices in San Francisco and New York, has announced the acquisition of Polypeptide Therapeutic Solutions, S.L. (PTS) from Columbus Venture Partners.
PTS is a Valencia-based leading GMP-grade manufacturer of polyamino-acid (PAA) based nanoparticle encapsulation technology for advanced drug delivery applications, including mRNA, DNA, cell therapies, gene therapies, biologics, vaccines, and small molecule therapies. PTS’ team of expert biochemists and polymeric material scientists are critical partners in the drug development and commercialization processes of some of the leading therapeutics companies in the world. The company’s service offerings include Preclinical Development, Technology Transfer, GMP Manufacturing, and Fill & Finish Services.
Columbus Venture Partners is a Spanish independent Venture Capital firm headquartered in Madrid with offices in Valencia that brings a unique approach to investing in outstanding early-stage and high-growth opportunities in the life sciences industry of Spain.
Arcline commented, “We believe that the success of nanoparticle delivery technologies in COVID-19 mRNA vaccines has permanently accelerated the funding, development, and adoption of these advanced drug delivery systems. PTS’ technology seeks to improve the efficiency, targeting, and safety profile of delivery systems for novel therapeutics, bringing urgently needed treatments to patients across multiple disease areas. We are excited to invest in PTS’ continued growth through the expansion of its GMP production and its technology portfolio.”
Cuatrecasas advised Arcline Investment Management with a Commercial team formed by partner and head of the New York office Antonio Baena (pictured left), senior associate Diego Pérez-Yarza and principal associate Sara Shackleford, all from New York. Partner Soraya Sáenz de Santamaría (pictured right), principal associate Jesús García and associates Sergio Ochagavía and Olga Corbal advised from the Madrid office, with significant support from the firm´s Competition, Tax, Labour and Intellectual Property areas.